Nintedanib Teva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR, and PDGFR. Inhibition of these receptors reduces fibroblast activation, angiogenesis, and extracellular matrix production, which together limit fibrotic tissue formation and impede tumor‑related blood vessel development.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s indication, weight, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Nintedanib in pregnancy and lactation are limited. The drug is generally not recommended for pregnant or nursing women unless the potential benefit justifies the potential risk. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The main alternative for idiopathic pulmonary fibrosis is pirfenidone, which has a different mechanism (inhibits TGF‑β signaling). Nintedanib targets multiple tyrosine kinases, offering broader inhibition of fibrotic pathways. Choice of therapy depends on patient tolerance, comorbidities, drug‑interaction profile, and physician judgment.

Store Nintedanib Teva at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, heat and direct sunlight to maintain stability.

Nintedanib Teva is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed.

The most serious adverse events include severe liver injury, arterial thromboembolic events such as myocardial infarction or stroke, and major bleeding. Patients should be monitored regularly for hepatic function, cardiovascular health, and signs of bleeding.

Nintedanib is contraindicated in patients with known hypersensitivity to the drug, those with active severe hepatic impairment, and individuals with a recent history of arterial thromboembolic events. Caution is also advised for patients with significant renal impairment or uncontrolled cardiovascular disease.